We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02811783
Recruitment Status : Terminated (Sponsor decision)
First Posted : June 23, 2016
Last Update Posted : October 28, 2022
Information provided by (Responsible Party):
Elorac, Inc.

Brief Summary:

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing.

Funding Source - FDA OOPD

Condition or disease Intervention/treatment Phase
Mycosis Fungoides Lymphoma, T-Cell, Cutaneous Sézary Syndrome Drug: Naloxone Hydrochloride Lotion, 0.5% Drug: Placebo Lotion Phase 3

Detailed Description:
There will be 160 subjects enrolled in the study. The study consists of a Screening Period of up to 7 days during which inclusion / exclusion criteria will be reviewed. Subjects meeting inclusion / exclusion criteria including the diagnostic criteria for MF or SS and a score of at least 5 on the 11-Point Numeric Rating Scale (NRS) for Pruritus will complete the one week Screening Period. Subjects will complete a daily diary for NRS for Pruritus scores and Sleep scores. At the end of the Screening Period, subjects who have a NRS for Pruritus score of at least 5 recorded in the diary on at least 4 of the 7 days preceding Day 0 will be eligible to continue. Baseline assessments will be recorded for vital signs, pruritic body surface area, skin integrity, PQOL, and laboratory results. The Baseline period will be followed by a 2 week Treatment Period 1 in which subjects will be randomized to Naloxone Lotion 0.5% or Placebo Lotion to be applied TID for 14 days. During the 2 week Treatment Period subjects will complete daily diaries of NRS for Pruritis scores and Sleep scores. On Day 14 subjects will return to the clinic to review diaries, adverse events (AEs), concomitant medications, and to record body surface area for pruritus, skin integrity, PQOL, and laboratory results. Subjects will then enter a Washout Period for up to 56 days until the subject again scores at least 5 on the NRS for Pruritus on 4 consecutive or 4 of the past 7 days or 56 days pass. Subjects will then enter a 2 week Treatment Period 2 during which the same procedures as Treatment Period 1 will be performed except subjects will receive the alternate treatment to that assigned in Treatment Period 1. Subjects will then have the option to enter a 26 Week Open Label Treatment Period 3 during which the same procedures as Treatment Period 1 and 2 will be performed except subjects will return only at Week 13 and Week 26 and all subjects will be treated with Naloxone Lotion 0.5%.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Actual Study Start Date : January 2017
Actual Primary Completion Date : September 2022
Actual Study Completion Date : September 2022

Arm Intervention/treatment
Active Comparator: Naloxone Hydrochloride Lotion, 0.5%
Naloxone Hydrochloride Lotion 0.5%
Drug: Naloxone Hydrochloride Lotion, 0.5%
Topical TID for 2 weeks

Placebo Comparator: Placebo Lotion
Placebo Lotion
Drug: Placebo Lotion
Topical TID for 2 weeks

Primary Outcome Measures :
  1. Numeric Rating Scale (NRS) for Pruritus [ Time Frame: Baseline and 2 Weeks ]
    Change from Baseline to Day 14 in average NRS for Pruritus for each Treatment Period

Secondary Outcome Measures :
  1. Responder Analysis - The difference in the proportion of subjects with a meaningful clinically significant improvement at the end of the two periods. [ Time Frame: Baseline and 2 Weeks ]
    The difference in the proportion of subjects with a meaningful clinically significant improvement at the end of the two periods. A clinically significant improvement is defined as an improvement of at least one category on the 4-point (none, mild, moderate, severe) Likert Scale verbal rating scale (VRS) and at least two points on the 11-point NRS for Pruritus. The NRS for Pruritus scores will be converted to VRS scores as follows for the analysis: 0=none, 1-3=mild, 4-6=moderate, and 7-10=severe.

  2. Numeric Rating Scale for Sleep [ Time Frame: Baseline and 1 and 2 weeks ]
    The change from Baseline at each week of the NRS for Sleep average score for each Treatment Period.

  3. Numeric Rating Scale for Pruritus [ Time Frame: Baseline and 1 week ]
    The change from Baseline at Week 1 of the NRS for Pruritus average score for each Treatment Period.

  4. Categorical Rating Scale (CRS) for Skin Integrity [ Time Frame: Baseline and 2 weeks ]
    The change from Baseline at Week 2 of the CRS for Skin Integrity for each Treatment Period.

  5. Pruritus Quality of Life Score (PQOL) [ Time Frame: Baseline and Day 14 of each Treatment period ]
    The change from Baseline in the final categorization of the PQOL at Day 14 of each Treatment Period

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

All subjects must meet the following criteria for admission into the study:

  1. Signed informed consent has been obtained.
  2. Subject is at least 21 years of age.
  3. Diagnosis of mycosis fungoides (MF) or Sézary syndrome (SS) will be based on a combination of histological, clinical, and immunophenotypical criteria. The histological criteria will be based on skin biopsy from the most representative skin area. The diagnostic criteria used for each subject will be specified in the case report forms and the specific classification of MF or SS will be identified. The TNMB system will be used to classify the stage of disease (See Section 8.4 for details).
  4. Completion of the mSWAT assessment.
  5. A history of pruritus that meets following criteria:

    At Screening Day -7:

    • present on a daily basis for greater than one month prior to Screening Day -7,
    • NRS for Pruritus score ≥5 as rated by the subject at the Day -7 Visit. Note: If the score is <5 and subject is taking or has taken a medication which may be affecting pruritus (e.g. systemic antihistamine or topical steroid), and if Investigator and subject agree, subject may washout or continue washout of medication and return for Day -7 Visit procedures after washout.

    At Baseline Period 1 Day 0:

    • NRS for Pruritus score of at least 5 recorded in the subject diary on at least 4 of the 7 days preceding Baseline Period 1 Day 0.
  6. Pruritic treatment area of 5-95% of the subject's total treatable body surface area.
  7. Subject can be expected to reliably follow treatment instructions and visit schedule.
  8. Non-pregnant, non-lactating females of childbearing potential who agree to use medically acceptable forms of birth control (abstinence, hormonal contraceptives, diaphragm with spermicide, condom with spermicide, or intrauterine device) throughout the study or females of non-childbearing potential (surgically sterile [hysterectomy or bilateral tubal ligation] or post-menopausal ≥ 1 year). A negative urine pregnancy test must be confirmed at Baseline screening for all female subjects who are not post-menopausal > 1 year or surgically sterile.
  9. The subject agrees not to begin any new concomitant medications during their participation in the study, with the exception of medications necessary to treat infection, and to continue any concomitant medication throughout the study.
  10. Subject has no visual or motor impairments that will make it difficult to complete the Daily Diary or apply the study medication.
  11. Subject is able to speak, read, and write English and agrees to participate and comply with the study procedures.
  12. Subject has a body mass index (BMI) between 18.5 and 30.5 kglm2 (see Appendix C, Body Mass Index Table) (subjects in PK subset only).

Exclusion Criteria:

Subjects meeting any of the following criteria will be excluded from study participation:

  1. Pregnant or lactating female.
  2. History of clinically significant heart failure.
  3. Myocardial infarction within the past six months.
  4. A history of ventricular arrhythmia requiring treatment.
  5. Any medical condition which would, in the Investigator's opinion, preclude the subject from successfully participating in the study.
  6. A known allergy to naloxone hydrochloride or any excipient in the formulation.
  7. Previous naloxone use for pruritus.
  8. Positive urine drug screen at Day 0 for opiates. Positive urine drug screen for anything other than opiates not explained, e.g., by concomitant medication, would also exclude the subject.
  9. Treatment with any of the following during the restricted time period prior to Day -7, and at any time during the study, is not allowed:

Medication/Treatment Restriction:

Systemic narcotic analgesics (e.g. morphine, codeine) 7 days, Topical antihistamines to any skin surface [e.g. Zonalon® (doxepin)] 7 days, Other investigational drugs (excluding any therapies for the treatment of MF or SS) 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02811783

Layout table for location information
United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
United States, California
City of Hope
Duarte, California, United States, 91010
Stanford University
Palo Alto, California, United States, 94304
United States, Florida
USSF Health Morsani Center for Advanced Healthcare
Tampa, Florida, United States, 33612
Cleveland Clinic Indian River Hospital
Vero Beach, Florida, United States, 32960
United States, Illinois
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States, 60611
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Indiana
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States, 46250
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
St. Louis University Dermatology
Saint Louis, Missouri, United States, 63104
Washington University School of Medicine St. Louis
Saint Louis, Missouri, United States, 63110
United States, New York
Stony Brook Dermatology
Stony Brook, New York, United States, 11790
United States, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Virginia
Inova Schar Cancer Institute
Fairfax, Virginia, United States, 22031
United States, Washington
University of Washington / Seattle Cancer Care Alliance (SCCA)
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Elorac, Inc.
Layout table for investigator information
Study Director: Scott B Phillips, MD Elorac, Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Elorac, Inc.
ClinicalTrials.gov Identifier: NCT02811783    
Other Study ID Numbers: EL-1007-01-01
1R01FD005396-01A1 ( U.S. FDA Grant/Contract )
First Posted: June 23, 2016    Key Record Dates
Last Update Posted: October 28, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Elorac, Inc.:
Mycosis Fungoides
opiate antagonist
Sézary Syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycosis Fungoides
Sezary Syndrome
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Bacterial Infections and Mycoses
Lymphoma, Non-Hodgkin
Skin Diseases
Skin Manifestations
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents